Alternate Day Buprenorphine Administration, Phase XII - 17

Phase 2

Completed

• Conditions: Opioid-Related Disorders

• Registration Number: NCT00000235
• Lead Sponsor: National Institute on Drug Abuse (NIDA)

Brief Summary

The purpose of this study is to determine if six times daily buprenorphine dose is effective in achieving 120 hour buprenorphine dosing.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 1999-09-20
• Study First Submitted QC: 1999-09-20
• Study First Posted: 1999-09-21
• Status Verified: 2002-12
• Last Update Submitted: 2005-08-16
• Last Update Posted: 2005-08-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Drug use
Opioid withdrawal
Opioid agonist effects
Dose choice

Trial Locations

Locations (1)

Treatment Research Center; 🇺🇸 Burlington, Vermont, United States